Exscientia (EXAI) said Wednesday it expects to receive in Q4 a total of $15 million in milestone payments after advancing two drug programs in its collaboration with Sanofi (SNY).
Exscientia said both compounds met the requirements set by both companies to enable a transition to an optimization phase in the collaboration.
The drug development company said it remains eligible to receive additional pre-commercial milestone payments of over $300 million and commercial milestones of over $300 million as well as tiered royalties as part of the Sanofi collaboration.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。